Please wait while the formulary information is being retrieved.
Drug overview for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
Generic name: clindamycin palmitate HCl (KLIN-da-MYE-sin)
Drug class: Clindamycin Systemic
Therapeutic class: Anti-Infective Agents
Clindamycin, a lincosamide antibiotic, is a derivative of lincomycin.
Clindamycin is used for the treatment of certain serious infections caused by susceptible aerobic gram-positive bacteria (staphylococci, streptococci, pneumococci) and for the treatment of certain serious infections caused by susceptible anaerobic bacteria. Use of clindamycin generally should be reserved for the treatment of serious infections when less toxic anti-infectives cannot be used (e.g., penicillin-allergic patients or other patients for whom a penicillin is inappropriate). Because clindamycin has been associated with potentially fatal colitis (see Cautions: GI Effects), the manufacturer recommends that clinicians consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Certain infections may require incision and drainage or other indicated surgical procedures in addition to anti-infective treatment. Use of clindamycin does not eliminate the need for surgical procedures when indicated. Because clindamycin does not distribute adequately into the CNS, the drug should not be used for the treatment of meningitis.
Generic name: clindamycin palmitate HCl (KLIN-da-MYE-sin)
Drug class: Clindamycin Systemic
Therapeutic class: Anti-Infective Agents
Clindamycin, a lincosamide antibiotic, is a derivative of lincomycin.
Clindamycin is used for the treatment of certain serious infections caused by susceptible aerobic gram-positive bacteria (staphylococci, streptococci, pneumococci) and for the treatment of certain serious infections caused by susceptible anaerobic bacteria. Use of clindamycin generally should be reserved for the treatment of serious infections when less toxic anti-infectives cannot be used (e.g., penicillin-allergic patients or other patients for whom a penicillin is inappropriate). Because clindamycin has been associated with potentially fatal colitis (see Cautions: GI Effects), the manufacturer recommends that clinicians consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Certain infections may require incision and drainage or other indicated surgical procedures in addition to anti-infective treatment. Use of clindamycin does not eliminate the need for surgical procedures when indicated. Because clindamycin does not distribute adequately into the CNS, the drug should not be used for the treatment of meningitis.
DRUG IMAGES
CLEOCIN PEDIATRIC 75 MG/5 ML
The following indications for CLEOCIN PEDIATRIC (clindamycin palmitate hcl) have been approved by the FDA:
Indications:
Anaerobic lung abscess
Anaerobic pelvic cellulitis
Anaerobic peritonitis
Anaerobic pneumonia
Anaerobic tubo-ovarian abscess
Bacterial sepsis
Bacteroides endomyometritis
Infectious disease of abdomen
Inflammatory disease of female pelvic organs
Intra-abdominal anaerobic abscess
Pleural empyema
Pneumococcal pneumonia
Postsurgical vaginal cuff anaerobic infections
Sepsis caused by anaerobic bacteria
Skin and skin structure anaerobic infection
Skin and skin structure infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcal pneumonia
Staphylococcus aureus skin and skin structure infection
Streptococcal pneumonia
Professional Synonyms:
Abdominal abscess due to anaerobic bacteria
Anaerobic sepsis
Bacteremia with sepsis
Bacterial septicemia
Endomyometritis due to Bacteroides species
Infection of skin and/or subcutaneous tissue
Infection of the lungs due to anaerobic bacteria
Intra-abdominal infection
Lung abscess due to anaerobic bacteria
Parametritis due to anaerobic bacteria
Pelvic cellulitis due to anaerobic bacteria
Peritonitis due to anaerobic bacteria
Pneumonia due to Staphylococcus species
Pneumonia due to Staphylococcus spp.
Pneumonia due to Streptococcus pneumoniae
Pneumonia due to Streptococcus species
Pneumonia due to Streptococcus spp.
Postsurgical anaerobic vaginal cuff infection
Pyothorax
Sepsis of uterine tissue due to Bacteroides species
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Staphylococcus aureus infection
Skin and soft tissue skin infection
Tubo-ovarian abscess due to anaerobic bacteria
Indications:
Anaerobic lung abscess
Anaerobic pelvic cellulitis
Anaerobic peritonitis
Anaerobic pneumonia
Anaerobic tubo-ovarian abscess
Bacterial sepsis
Bacteroides endomyometritis
Infectious disease of abdomen
Inflammatory disease of female pelvic organs
Intra-abdominal anaerobic abscess
Pleural empyema
Pneumococcal pneumonia
Postsurgical vaginal cuff anaerobic infections
Sepsis caused by anaerobic bacteria
Skin and skin structure anaerobic infection
Skin and skin structure infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcal pneumonia
Staphylococcus aureus skin and skin structure infection
Streptococcal pneumonia
Professional Synonyms:
Abdominal abscess due to anaerobic bacteria
Anaerobic sepsis
Bacteremia with sepsis
Bacterial septicemia
Endomyometritis due to Bacteroides species
Infection of skin and/or subcutaneous tissue
Infection of the lungs due to anaerobic bacteria
Intra-abdominal infection
Lung abscess due to anaerobic bacteria
Parametritis due to anaerobic bacteria
Pelvic cellulitis due to anaerobic bacteria
Peritonitis due to anaerobic bacteria
Pneumonia due to Staphylococcus species
Pneumonia due to Staphylococcus spp.
Pneumonia due to Streptococcus pneumoniae
Pneumonia due to Streptococcus species
Pneumonia due to Streptococcus spp.
Postsurgical anaerobic vaginal cuff infection
Pyothorax
Sepsis of uterine tissue due to Bacteroides species
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Staphylococcus aureus infection
Skin and soft tissue skin infection
Tubo-ovarian abscess due to anaerobic bacteria
The following dosing information is available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
Dosage of clindamycin hydrochloride, clindamycin palmitate hydrochloride, and clindamycin phosphate is expressed in terms of clindamycin.
Dosage and duration of treatment depend on the severity of the infection. If clindamycin is used in infections caused by Streptococcus pyogenes (group A beta-hemolytic streptococci; GAS), therapy should be continued for at least 10 days. At least 6 weeks of therapy may be required for certain serious infections (e.g., osteomyelitis).
When clindamycin oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum clindamycin dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in neonates 7 days of age or younger, the American Academy of Pediatrics (AAP) recommends a dosage of 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an oral clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
When clindamycin capsules are used in pediatric patients able to swallow capsules, the manufacturer recommends 8-16 mg/kg daily given in 3 or 4 equally divided doses for the treatment of serious infections or 16-20 mg/kg daily given in 3 or 4 equally divided doses for more severe infections.
When the oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in pediatric patients beyond the neonatal period, AAP recommends a dosage of 10-25 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 30-40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The usual adult dosage of oral clindamycin is 150-300 mg every 6 hours for the treatment of serious infections or 300-450 mg every 6 hours for the treatment of more severe infections.
The manufacturer recommends that neonates younger than 1 month of age receive IM or IV clindamycin in a dosage of 15-20 mg/kg daily given in 3 or 4 equally divided doses. The lower dosage may be adequate for small, premature neonates.
When IM or IV clindamycin is used in neonates 7 days of age or younger, AAP recommends 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an IM or IV clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
The IM or IV dosage of clindamycin recommended by the manufacturer for infants and children 1 month of age or older is 20-40 mg/kg daily administered in 3 or 4 equally divided doses; the higher dosage should be used for more severe infections. Alternatively, the manufacturer states that these infants and children may receive 350 mg/m2 daily for the treatment of serious infections or 450 mg/m2 daily for the treatment of more severe infections.
In pediatric patients beyond the neonatal period, AAP recommends an IM or IV clindamycin dosage of 20-30 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The recommended adult dosage of IM or IV clindamycin is 600 mg to 1.2 g daily given in 2-4 equally divided doses for the treatment of serious infections or 1.2-2.7
g daily given in 2-4 equally divided doses for the treatment of more severe infections. In the treatment of life-threatening infections, adult IV dosage may be increased to a maximum of 4.8 g daily.
If continuous IV infusion of clindamycin is used to maintain serum clindamycin concentrations above 4-6 mcg/mL in adults, an initial dose is given by rapid IV infusion prior to continuous IV infusion. (See Table 1.)
Dosage and duration of treatment depend on the severity of the infection. If clindamycin is used in infections caused by Streptococcus pyogenes (group A beta-hemolytic streptococci; GAS), therapy should be continued for at least 10 days. At least 6 weeks of therapy may be required for certain serious infections (e.g., osteomyelitis).
When clindamycin oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum clindamycin dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in neonates 7 days of age or younger, the American Academy of Pediatrics (AAP) recommends a dosage of 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an oral clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
When clindamycin capsules are used in pediatric patients able to swallow capsules, the manufacturer recommends 8-16 mg/kg daily given in 3 or 4 equally divided doses for the treatment of serious infections or 16-20 mg/kg daily given in 3 or 4 equally divided doses for more severe infections.
When the oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in pediatric patients beyond the neonatal period, AAP recommends a dosage of 10-25 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 30-40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The usual adult dosage of oral clindamycin is 150-300 mg every 6 hours for the treatment of serious infections or 300-450 mg every 6 hours for the treatment of more severe infections.
The manufacturer recommends that neonates younger than 1 month of age receive IM or IV clindamycin in a dosage of 15-20 mg/kg daily given in 3 or 4 equally divided doses. The lower dosage may be adequate for small, premature neonates.
When IM or IV clindamycin is used in neonates 7 days of age or younger, AAP recommends 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an IM or IV clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
The IM or IV dosage of clindamycin recommended by the manufacturer for infants and children 1 month of age or older is 20-40 mg/kg daily administered in 3 or 4 equally divided doses; the higher dosage should be used for more severe infections. Alternatively, the manufacturer states that these infants and children may receive 350 mg/m2 daily for the treatment of serious infections or 450 mg/m2 daily for the treatment of more severe infections.
In pediatric patients beyond the neonatal period, AAP recommends an IM or IV clindamycin dosage of 20-30 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The recommended adult dosage of IM or IV clindamycin is 600 mg to 1.2 g daily given in 2-4 equally divided doses for the treatment of serious infections or 1.2-2.7
g daily given in 2-4 equally divided doses for the treatment of more severe infections. In the treatment of life-threatening infections, adult IV dosage may be increased to a maximum of 4.8 g daily.
If continuous IV infusion of clindamycin is used to maintain serum clindamycin concentrations above 4-6 mcg/mL in adults, an initial dose is given by rapid IV infusion prior to continuous IV infusion. (See Table 1.)
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CLEOCIN PEDIATRIC 75 MG/5 ML | Maintenance | Adults take 10 milliliters (150 mg) by oral route every 6 hours |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CLINDAMYCIN (PEDI) 75 MG/5 ML | Maintenance | Adults take 10 milliliters (150 mg) by oral route every 6 hours |
The following drug interaction information is available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Lincosamides/Kaolin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Adsorption of antibiotic to kaolin-pectin. CLINICAL EFFECTS: Decreased or delayed pharmacological effect of the antibiotic. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Administer the antibiotic two hours after kaolin-pectin. DISCUSSION: When kaolin-pectin suspension was coadministered with lincomycin only 9% of the antibiotic was absorbed. Coadministration of kaolin-pectin and clindamycin decreased the peak clindamycin concentration by 61% and delayed the time to reach peak serum concentration by 1.5 hours. |
KAOLIN |
| Neuromuscular Blocking Agents/Lincosamides SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Lincosamides appear to augment the neuromuscular blocking effects of nondepolarizing muscle relaxants. CLINICAL EFFECTS: The effects of nondepolarizing neuromuscular relaxants may be prolonged leading to profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Monitor respiratory function of the patient and provide the necessary support. In patients who have received nondepolarizing muscle relaxants, avoid use of lincosamides in the recovery room. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Lincomycin has been reported to augment the neuromuscular blocking effect of pancuronium in seven anesthetized patients. The effect was readily antagonized by neostigmine administration. In a case report, clindamycin produced prolonged neuromuscular blockade in a patient who had received pancuronium. Neostigmine was ineffective in antagonizing the blockade. |
ANECTINE, ATRACURIUM BESYLATE, BOTOX, BOTOX COSMETIC, CISATRACURIUM BESYLATE, DAXXIFY, DYSPORT, JEUVEAU, MYOBLOC, NIMBEX, QUELICIN, ROCURONIUM BROMIDE, SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE-NACL, VECURONIUM BROMIDE, VECURONIUM BROMIDE-WATER, XEOMIN |
The following contraindication information is available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Bloody stools |
| Clostridioides difficile infection |
| Crohn's disease |
| Diarrhea |
| Myasthenia gravis |
| Ulcerative colitis |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Atopic dermatitis |
| Disease of liver |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 26 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Clostridioides difficile infection |
Abnormal hepatic function tests Allergic dermatitis Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
|
Acute generalized exanthematous pustulosis Acute renal failure Agranulocytosis Anaphylaxis Angioedema Bullous dermatitis Cholestasis DRESS syndrome Drug-induced hepatitis Eosinophilia Erythema multiforme Esophageal ulcer Exfoliative dermatitis Hypersensitivity drug reaction Jaundice Kidney disease with reduction in glomerular filtration rate (GFr) Neutropenic disorder Stevens-johnson syndrome Thrombocytopenic disorder Toxic epidermal necrolysis |
There are 15 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Diarrhea Nausea Vomiting |
Erythema Esophagitis Genital organ pruritus Oral candidiasis Vaginitis Vulvovaginal candidiasis |
| Rare/Very Rare |
|---|
|
Arthritis Azotemia Dysgeusia Maculopapular rash Thrombophlebitis |
The following precautions are available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| Clindamycin (Systemic) | 1 Day – 18 Years | Monitor hepatic, renal function and bowel frequency. |
Reproduction studies in rats and mice using oral or parenteral dosages of clindamycin up to 600 mg/kg daily (3.2 and 1.6 times, respectively, the maximum recommended human oral dosage or 2.1 and 1.1 times, respectively, the maximum recommended human parenteral dosage on a mg/m2 basis) have not revealed evidence of teratogenicity. In clinical trials that included pregnant women, systemic clindamycin administered during the second and third trimesters was not associated with an increased frequency of congenital abnormalities. There are no adequate and well-controlled studies to date using clindamycin in pregnant women during the first trimester of pregnancy.
Because animal reproduction studies are not always predictive of human response, clindamycin should be used during pregnancy only when clearly needed. Clindamycin phosphate injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Because animal reproduction studies are not always predictive of human response, clindamycin should be used during pregnancy only when clearly needed. Clindamycin phosphate injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
| Drug/Drug Class | Severity | Precaution Description | Pregnancy Category Description |
|---|---|---|---|
| Clindamycin (oral, Inj) | 2 | Limited human data do not suggest a clear association for development toxicity | No fda rating but may have precautions or warnings; may have animal and/or human studies or pre or post marketing information. |
Clindamycin is distributed into milk (see Pharmacokinetics: Distribution), and has the potential to cause adverse effects on the GI flora of breast-fed infants. The manufacturer states that use of oral or IV clindamycin in the mother is not a reason to discontinue breast-feeding; however, it may be preferable to use an alternate anti-infective. If clindamycin is used in a breast-feeding mother, the infant should be monitored for possible adverse effects on GI flora, including diarrhea and candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis. The benefits of breast-feeding and the importance of clindamycin to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
| Drug Name | Excretion Potential | Effect on Infant | Notes |
|---|---|---|---|
| Clindamycin (oral, Inj) | Excreted.This drug is known to be excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Gi flora changes possible; monitor infant for diarrhea |
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl):
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse. Consult your doctor or pharmacist for details and an appropriate treatment plan.
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse. Consult your doctor or pharmacist for details and an appropriate treatment plan.
The following icd codes are available for CLEOCIN PEDIATRIC (clindamycin palmitate hcl)'s list of indications:
| Anaerobic lung abscess | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| J85.1 | Abscess of lung with pneumonia |
| J85.2 | Abscess of lung without pneumonia |
| Anaerobic pelvic cellulitis | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N73.0 | Acute parametritis and pelvic cellulitis |
| N73.1 | Chronic parametritis and pelvic cellulitis |
| N73.2 | Unspecified parametritis and pelvic cellulitis |
| Anaerobic peritonitis | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| K65.0 | Generalized (acute) peritonitis |
| K65.2 | Spontaneous bacterial peritonitis |
| T85.71 | Infection and inflammatory reaction due to peritoneal dialysis catheter |
| T85.71xA | Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter |
| Anaerobic pneumonia | |
| J15.8 | Pneumonia due to other specified bacteria |
| Anaerobic tubo-ovarian abscess | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N70 | Salpingitis and oophoritis |
| N70.0 | Acute salpingitis and oophoritis |
| N70.01 | Acute salpingitis |
| N70.02 | Acute oophoritis |
| N70.03 | Acute salpingitis and oophoritis |
| N70.1 | Chronic salpingitis and oophoritis |
| N70.11 | Chronic salpingitis |
| N70.12 | Chronic oophoritis |
| N70.13 | Chronic salpingitis and oophoritis |
| N70.9 | Salpingitis and oophoritis, unspecified |
| N70.91 | Salpingitis, unspecified |
| N70.92 | Oophoritis, unspecified |
| N70.93 | Salpingitis and oophoritis, unspecified |
| Bacterial sepsis | |
| A02.1 | Salmonella sepsis |
| A20.7 | Septicemic plague |
| A22.7 | Anthrax sepsis |
| A26.7 | Erysipelothrix sepsis |
| A32.7 | Listerial sepsis |
| A40 | Streptococcal sepsis |
| A40.0 | Sepsis due to streptococcus, group A |
| A40.1 | Sepsis due to streptococcus, group B |
| A40.3 | Sepsis due to streptococcus pneumoniae |
| A40.8 | Other streptococcal sepsis |
| A40.9 | Streptococcal sepsis, unspecified |
| A41 | Other sepsis |
| A41.0 | Sepsis due to staphylococcus aureus |
| A41.01 | Sepsis due to methicillin susceptible staphylococcus aureus |
| A41.02 | Sepsis due to methicillin resistant staphylococcus aureus |
| A41.1 | Sepsis due to other specified staphylococcus |
| A41.2 | Sepsis due to unspecified staphylococcus |
| A41.3 | Sepsis due to hemophilus influenzae |
| A41.4 | Sepsis due to anaerobes |
| A41.5 | Sepsis due to other gram-negative organisms |
| A41.50 | Gram-negative sepsis, unspecified |
| A41.51 | Sepsis due to escherichia coli [e. coli] |
| A41.52 | Sepsis due to pseudomonas |
| A41.53 | Sepsis due to serratia |
| A41.54 | Sepsis due to acinetobacter baumannii |
| A41.59 | Other gram-negative sepsis |
| A41.8 | Other specified sepsis |
| A41.81 | Sepsis due to enterococcus |
| A41.89 | Other specified sepsis |
| A41.9 | Sepsis, unspecified organism |
| A42.7 | Actinomycotic sepsis |
| A54.86 | Gonococcal sepsis |
| O03.37 | Sepsis following incomplete spontaneous abortion |
| O08.82 | Sepsis following ectopic and molar pregnancy |
| O85 | Puerperal sepsis |
| O86.04 | Sepsis following an obstetrical procedure |
| P36 | Bacterial sepsis of newborn |
| P36.0 | Sepsis of newborn due to streptococcus, group B |
| P36.1 | Sepsis of newborn due to other and unspecified streptococci |
| P36.10 | Sepsis of newborn due to unspecified streptococci |
| P36.19 | Sepsis of newborn due to other streptococci |
| P36.2 | Sepsis of newborn due to staphylococcus aureus |
| P36.3 | Sepsis of newborn due to other and unspecified staphylococci |
| P36.30 | Sepsis of newborn due to unspecified staphylococci |
| P36.39 | Sepsis of newborn due to other staphylococci |
| P36.4 | Sepsis of newborn due to escherichia coli |
| P36.5 | Sepsis of newborn due to anaerobes |
| P36.8 | Other bacterial sepsis of newborn |
| P36.9 | Bacterial sepsis of newborn, unspecified |
| R65.2 | Severe sepsis |
| T81.12 | Postprocedural septic shock |
| T81.12xA | Postprocedural septic shock, initial encounter |
| T81.44 | Sepsis following a procedure |
| T81.44xA | Sepsis following a procedure, initial encounter |
| Bacteroides endomyometritis | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| N71 | Inflammatory disease of uterus, except cervix |
| N71.0 | Acute inflammatory disease of uterus |
| N71.1 | Chronic inflammatory disease of uterus |
| N71.9 | Inflammatory disease of uterus, unspecified |
| O86.12 | Endometritis following delivery |
| Infectious disease of abdomen | |
| A51.1 | Primary anal syphilis |
| K35 | Acute appendicitis |
| K35.2 | Acute appendicitis with generalized peritonitis |
| K35.20 | Acute appendicitis with generalized peritonitis, without abscess |
| K35.200 | Acute appendicitis with generalized peritonitis, without perforation or abscess |
| K35.201 | Acute appendicitis with generalized peritonitis, with perforation, without abscess |
| K35.209 | Acute appendicitis with generalized peritonitis, without abscess, unspecified as to perforation |
| K35.21 | Acute appendicitis with generalized peritonitis, with abscess |
| K35.210 | Acute appendicitis with generalized peritonitis, without perforation, with abscess |
| K35.211 | Acute appendicitis with generalized peritonitis, with perforation and abscess |
| K35.219 | Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation |
| K35.3 | Acute appendicitis with localized peritonitis |
| K35.30 | Acute appendicitis with localized peritonitis, without perforation or gangrene |
| K35.31 | Acute appendicitis with localized peritonitis and gangrene, without perforation |
| K35.32 | Acute appendicitis with perforation, localized peritonitis, and gangrene, without abscess |
| K35.33 | Acute appendicitis with perforation, localized peritonitis, and gangrene, with abscess |
| K35.8 | Other and unspecified acute appendicitis |
| K35.80 | Unspecified acute appendicitis |
| K35.89 | Other acute appendicitis |
| K35.890 | Other acute appendicitis without perforation or gangrene |
| K35.891 | Other acute appendicitis without perforation, with gangrene |
| K65.0 | Generalized (acute) peritonitis |
| K65.2 | Spontaneous bacterial peritonitis |
| Inflammatory disease of female pelvic organs | |
| N70 | Salpingitis and oophoritis |
| N70.0 | Acute salpingitis and oophoritis |
| N70.01 | Acute salpingitis |
| N70.02 | Acute oophoritis |
| N70.03 | Acute salpingitis and oophoritis |
| N70.1 | Chronic salpingitis and oophoritis |
| N70.11 | Chronic salpingitis |
| N70.12 | Chronic oophoritis |
| N70.13 | Chronic salpingitis and oophoritis |
| N70.9 | Salpingitis and oophoritis, unspecified |
| N70.91 | Salpingitis, unspecified |
| N70.92 | Oophoritis, unspecified |
| N70.93 | Salpingitis and oophoritis, unspecified |
| N71 | Inflammatory disease of uterus, except cervix |
| N71.0 | Acute inflammatory disease of uterus |
| N71.1 | Chronic inflammatory disease of uterus |
| N71.9 | Inflammatory disease of uterus, unspecified |
| N72 | Inflammatory disease of cervix uteri |
| N73 | Other female pelvic inflammatory diseases |
| N73.0 | Acute parametritis and pelvic cellulitis |
| N73.1 | Chronic parametritis and pelvic cellulitis |
| N73.2 | Unspecified parametritis and pelvic cellulitis |
| N73.3 | Female acute pelvic peritonitis |
| N73.4 | Female chronic pelvic peritonitis |
| N73.5 | Female pelvic peritonitis, unspecified |
| N73.8 | Other specified female pelvic inflammatory diseases |
| N73.9 | Female pelvic inflammatory disease, unspecified |
| Intra-abdominal anaerobic abscess | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| D73.3 | Abscess of spleen |
| K35.21 | Acute appendicitis with generalized peritonitis, with abscess |
| K35.210 | Acute appendicitis with generalized peritonitis, without perforation, with abscess |
| K35.211 | Acute appendicitis with generalized peritonitis, with perforation and abscess |
| K35.219 | Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation |
| K35.33 | Acute appendicitis with perforation, localized peritonitis, and gangrene, with abscess |
| K50.014 | Crohn's disease of small intestine with abscess |
| K50.114 | Crohn's disease of large intestine with abscess |
| K50.814 | Crohn's disease of both small and large intestine with abscess |
| K50.914 | Crohn's disease, unspecified, with abscess |
| K51.014 | Ulcerative (chronic) pancolitis with abscess |
| K51.214 | Ulcerative (chronic) proctitis with abscess |
| K51.314 | Ulcerative (chronic) rectosigmoiditis with abscess |
| K51.414 | Inflammatory polyps of colon with abscess |
| K51.514 | Left sided colitis with abscess |
| K51.814 | Other ulcerative colitis with abscess |
| K51.914 | Ulcerative colitis, unspecified with abscess |
| K57.0 | Diverticulitis of small intestine with perforation and abscess |
| K57.00 | Diverticulitis of small intestine with perforation and abscess without bleeding |
| K57.01 | Diverticulitis of small intestine with perforation and abscess with bleeding |
| K57.2 | Diverticulitis of large intestine with perforation and abscess |
| K57.20 | Diverticulitis of large intestine with perforation and abscess without bleeding |
| K57.21 | Diverticulitis of large intestine with perforation and abscess with bleeding |
| K57.4 | Diverticulitis of both small and large intestine with perforation and abscess |
| K57.40 | Diverticulitis of both small and large intestine with perforation and abscess without bleeding |
| K57.41 | Diverticulitis of both small and large intestine with perforation and abscess with bleeding |
| K57.8 | Diverticulitis of intestine, part unspecified, with perforation and abscess |
| K57.80 | Diverticulitis of intestine, part unspecified, with perforation and abscess without bleeding |
| K57.81 | Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding |
| K63.0 | Abscess of intestine |
| K65.1 | Peritoneal abscess |
| K68.1 | Retroperitoneal abscess |
| K68.11 | Postprocedural retroperitoneal abscess |
| K68.12 | Psoas muscle abscess |
| K68.19 | Other retroperitoneal abscess |
| K75.0 | Abscess of liver |
| N15.1 | Renal and perinephric abscess |
| N34.0 | Urethral abscess |
| N41.2 | Abscess of prostate |
| Pleural empyema | |
| J86 | Pyothorax |
| J86.0 | Pyothorax with fistula |
| J86.9 | Pyothorax without fistula |
| Pneumococcal pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| Postsurgical vaginal cuff anaerobic infections | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N76.0 | Acute vaginitis |
| T81.43 | Infection following a procedure, organ and space surgical site |
| T81.43xA | Infection following a procedure, organ and space surgical site, initial encounter |
| Sepsis caused by anaerobic bacteria | |
| A41.4 | Sepsis due to anaerobes |
| P36.5 | Sepsis of newborn due to anaerobes |
| Skin and skin structure anaerobic infection | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin and skin structure infection | |
| H05.01 | Cellulitis of orbit |
| H05.011 | Cellulitis of right orbit |
| H05.012 | Cellulitis of left orbit |
| H05.013 | Cellulitis of bilateral orbits |
| H05.019 | Cellulitis of unspecified orbit |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| K12.2 | Cellulitis and abscess of mouth |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| Skin and skin structure strep. pyogenes infection | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Staphylococcal pneumonia | |
| J15.2 | Pneumonia due to staphylococcus |
| J15.20 | Pneumonia due to staphylococcus, unspecified |
| J15.21 | Pneumonia due to staphylococcus aureus |
| J15.211 | Pneumonia due to methicillin susceptible staphylococcus aureus |
| J15.212 | Pneumonia due to methicillin resistant staphylococcus aureus |
| J15.29 | Pneumonia due to other staphylococcus |
| Staphylococcus aureus skin and skin structure infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.02 | Furuncle of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.12 | Furuncle of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.22 | Furuncle of trunk |
| L02.221 | Furuncle of abdominal wall |
| L02.222 | Furuncle of back [any part, except buttock] |
| L02.223 | Furuncle of chest wall |
| L02.224 | Furuncle of groin |
| L02.225 | Furuncle of perineum |
| L02.226 | Furuncle of umbilicus |
| L02.229 | Furuncle of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.32 | Furuncle of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.42 | Furuncle of limb |
| L02.421 | Furuncle of right axilla |
| L02.422 | Furuncle of left axilla |
| L02.423 | Furuncle of right upper limb |
| L02.424 | Furuncle of left upper limb |
| L02.425 | Furuncle of right lower limb |
| L02.426 | Furuncle of left lower limb |
| L02.429 | Furuncle of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.52 | Furuncle hand |
| L02.521 | Furuncle right hand |
| L02.522 | Furuncle left hand |
| L02.529 | Furuncle unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.62 | Furuncle of foot |
| L02.621 | Furuncle of right foot |
| L02.622 | Furuncle of left foot |
| L02.629 | Furuncle of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.82 | Furuncle of other sites |
| L02.821 | Furuncle of head [any part, except face] |
| L02.828 | Furuncle of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.92 | Furuncle, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| Streptococcal pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| J15.3 | Pneumonia due to streptococcus, group B |
| J15.4 | Pneumonia due to other streptococci |
Formulary Reference Tool